GERMAN pharmaceutical giant Merck and a US partner reported promising results yesterday in trials of a drug administered orally to fight Covid-19, saying it helps reduce patients’ viral load.
“At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data,” said Wendy Painter, chief medical officer of the US firm, Ridgeback Biotherapeutics.